A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT ID: NCT05031780
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
286 participants
INTERVENTIONAL
2022-02-11
2030-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 2: Mitapivat 50 mg BID
Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.
Mitapivat
Mitapivat tablets
Phase 2: Mitapivat 100 mg BID
Double-blind Period: Mitapivat 100 mg BID for 12 weeks.
Mitapivat
Mitapivat tablets
Phase 2: Placebo
Double-blind Period: Mitapivat-matching placebo for 12 weeks.
Mitapivat-matching placebo
Placebo to match 50 mg or 100 mg tablets
Phase 2: Open-Label Extension Period
Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after.
Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after.
Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after.
Mitapivat
Mitapivat tablets
Phase 3: Mitapivat 100 mg BID
Double-blind Period: Mitapivat 100 mg BID for 52 weeks.
Mitapivat
Mitapivat tablets
Phase 3: Placebo
Double-blind Period: Mitapivat-matching placebo for 52 weeks.
Mitapivat-matching placebo
Placebo to match 100 mg tablets
Phase 3: Open-Label Extension Period
Participants may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period.
Participants who received mitapivat-matching placebo in the double-blind period, may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period.
Mitapivat
Mitapivat tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mitapivat
Mitapivat tablets
Mitapivat-matching placebo
Placebo to match 50 mg or 100 mg tablets
Mitapivat-matching placebo
Placebo to match 100 mg tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented diagnosis of sickle cell disease (SCD) (HbSS, HbSC \[combined heterozygosity for hemoglobins S and C\], HbS/beta 0- thalassemia, HbS/ beta plus thalassemia, or other sickle cell syndrome variants);
* At least 2 SCPCs and no more than 10 SCPCs in the past 12 months;
* Hemoglobin at least 5.5 and 10.5 gram per deciliter (g/dL) at the most. Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the Screening Period;
* If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before starting study drug. Discontinuation of hydroxyurea requires a 90-day washout prior to informed assent/consent;
* Women capable of becoming pregnant must agree to use 2 forms of contraception.
Exclusion Criteria
* Receiving regularly scheduled transfusions;
* Hepatobiliary disorders including but not limited to significant liver disease or gallbladder disease;
* Severe kidney disease;
* Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
* Currently receiving treatment with a disease-modifying therapy for SCD (eg, voxelotor, crizanlizumab, L-glutamine), with the exception of hydroxyurea. The last dose of voxelotor, crizanlizumab, and L-glutamine must have been administered at least 90 days before randomization;
* Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered at least 90 days before starting study drug;
* Received treatment on another investigational trial within 90 days prior to start of study drug or plans to participate in another investigational drug trial;
* Taking medications that are strong inhibitors of CYP3A4/5 or strong inducers of CYP3A4 that cannot be stopped in an acceptable timeframe before starting study drug (timeframe will be discussed with your doctor).
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agios Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California San Diego
La Jolla, California, United States
UCLA Health
Los Angeles, California, United States
Children's Hospital Oakland
Oakland, California, United States
University of Connecticut Health Center
Farmington, Connecticut, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Sylvester Comprehensive Cancer Center-Miami
Miami, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Riley Hospital For Children
Indianapolis, Indiana, United States
LSU Health Sciences Center - Shreveport
Shreveport, Louisiana, United States
National Heart Lung and Blood Institute
Bethesda, Maryland, United States
Kaiser Permanente - Largo Medical Center
Largo, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Boston Medical Center & Boston University School of Medicine
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Children's Hospital of Michigan
Detroit, Michigan, United States
Southern Specialty Clinic
Flowood, Mississippi, United States
Mississippi Center for Advanced Medicine
Madison, Mississippi, United States
Cure 4 The Kids Foundation, A Division of Roseman University of Health Sciences
Las Vegas, Nevada, United States
East Carolina University - Brody School of Medicine
Greenville, North Carolina, United States
Penn Medicine - University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States
Lifespan at Rhode Island Hospital
Providence, Rhode Island, United States
University of Texas Health Science Center of Houston
Houston, Texas, United States
Texas Children's Hospital
Houston, Texas, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Seattle Cancer Care Alliance, University of Washington
Seattle, Washington, United States
Hôpital Erasme
Anderlecht, Brussels Capital, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Brussels Capital, Belgium
ZAS Cadix
Antwerp, , Belgium
CHR de la Citadelle
Liège, , Belgium
Clinique CHC MontLégia
Liège, , Belgium
Multihemo Servicos Medicos S/A
Recife, Pernambuco, Brazil
Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas da Unicamp
Campinas, São Paulo, Brazil
Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, São Paulo, Brazil
Praxis Pesquisa Medica
Santo André, São Paulo, Brazil
HEMORIO Instituto Nacional de Hematologia
Rio de Janeiro, , Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo
São Paulo, , Brazil
McMaster University - St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
CHU Montreal
Montreal, Quebec, Canada
McGill University Health Center
Montreal, Quebec, Canada
Hopitaux de La Timone
Marseille, Bouches-du-Rhône, France
Hôpital Pellegrin, CHU de Bordeaux
Bordeaux, Gironde, France
CHU Guadeloupe
Pointe à Pitre, Guadeloupe, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, Haute-Garonne, France
CHU Hôpital Henri Mondor
Créteil, Val-de-Marne, France
Hôpital Européen Georges Pompidou
Paris, Île-de-France Region, France
Universitätsklinikum Essen
Essen, , Germany
Universitätsklinikum Regensburg
Regensburg, , Germany
HaEmek Medical Center
Afula, , Israel
Rambam Medical Center
Haifa, Ḥeifā, Israel
Ziv Medical Center
Safed, Ḥeifā, Israel
A.O.R.N. "A. Cardarelli"
Napoli, Campania, Italy
AOU dell'Università degli Studi della Campania Luigi Vanvitelli
Napoli, Campania, Italy
Azienda Ospedaliero Universitaria Di Modena Policlinico
Modena, Emilia-Romagna, Italy
IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN
Rome, Lazio, Italy
Ente Ospedaliero Ospedali Galliera
Genoa, Liguria, Italy
Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello
Palermo, Sicily, Italy
Kemri Usamru
Kisumu, Western, Kenya
Kondele Children's Hospital
Kisumu, , Kenya
Victoria Biomedical Research Institute (VIBRI)
Kisumu, , Kenya
KEMRI CRDR Clinical Research Clinic Nairobi
Nairobi, , Kenya
KEMRI/CRDR Siaya Clinical Research Annex
Nairobi, , Kenya
Strathmore University
Nairobi, , Kenya
Gertrude's Children's Hospital
Nairobi, , Kenya
American University of Beirut Medical Center
Beirut, Beyrouth, Lebanon
Nini Hospital
Tarablus, Mohafazat Liban-Nord, Lebanon
American University of Beirut Medical Center
Beirut, , Lebanon
Hammoud Hospital University Medical Center
Sidon, , Lebanon
Erasmus MC
Rotterdam, South Holland, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, , Netherlands
National Hospital Abuja
Abuja, Federal Capital Territory, Nigeria
University of Abuja Teaching Hospital
Abuja, Federal Capital Territory, Nigeria
Lagos University Teaching Hospital
Surulere, Lagos, Nigeria
Sultan Qaboos University Hospital, Hematology Department, COM&HS
Muscat, Musqal, Oman
King Khalid University Hospital
Riyadh, Ar Riya, Saudi Arabia
King Abdullah International Medical Research Center
Riyadh, , Saudi Arabia
Hacettepe University
Ankara, Adana, Turkey (Türkiye)
Acibadem Adana Hospital
Seyhan, Adana, Turkey (Türkiye)
Evelina Children's Hospital
London, City of London, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, , United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, , United Kingdom
King's College Hospital NHS Foundation Trust
London, , United Kingdom
Hammersmith Hospital
London, , United Kingdom
University College London Hospitals (UCLH)
London, , United Kingdom
Manchester Royal Infirmary, Manchester University NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial. Lancet Haematol. 2025 Jan;12(1):e35-e44. doi: 10.1016/S2352-3026(24)00319-3. Epub 2024 Dec 4.
van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Rijneveld AW, Cnossen MH, Nur E, Biemond BJ, Bartels M, Jans JJM, van Solinge WW, Schutgens REG, van Wijk R, van Beers EJ. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. Blood Adv. 2023 Dec 26;7(24):7539-7550. doi: 10.1182/bloodadvances.2023011477.
Obadina M, Wilson S, Derebail VK, Little J. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations. Kidney360. 2023 Jul 1;4(7):997-1005. doi: 10.34067/KID.0000000000000162. Epub 2023 May 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-001674-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AG348-C-020
Identifier Type: -
Identifier Source: org_study_id